All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Mebendazole Disrupts Nucleotide Metabolism in Gastric Cancer (2026)
A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.
Curcumin Triggers Ferroptosis in Thyroid Cancer via GPX4 Downregulation (2026 Study)
A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.
Drug Repurposing for Renal Cell Carcinoma: Ivermectin and Antiparasitics Reviewed (2026)
A July 2026 review evaluates repurposed drugs — including ivermectin and artesunate — against renal cell carcinoma, identifying multiple targetable signalling pathways in preclinical models.
Antiparasitic Drugs in Stage IV Cancer: 6-Patient Case Series (Integrative Medicine, 2026)
A 2026 case series in Integrative Medicine describes 6 stage IV cancer patients who showed prolonged survival after AMA-guided antiparasitic protocols including ivermectin and mebendazole.
Ivermectin Inhibits Estrogen Receptor and HER2 Pathways in Endocrine-Resistant Breast Cancer
Researchers at Chulalongkorn University found that ivermectin significantly suppressed estrogen-induced proliferation and downregulated ER, HER2, and TGF-β pathway markers in endocrine-resistant breast cancer cells, suggesting potential as a repurposed agent to overcome hormonal therapy resistance.
Mebendazole Reprograms Oncogenic Networks Across Multiple Cancer Types
Researchers found that mebendazole at 0.7 µM reprogrammed oncogenic and tumor-suppressor networks across eight cancer cell lines, suppressing ENOX2 and MMP2 while activating RASSF1A by over 200-fold.
Ivermectin and Metformin Combination Promotes Autophagy in Breast Cancer via PI3K/AKT/mTOR Pathway
Chinese researchers found that combining ivermectin with metformin significantly inhibited MCF-7 breast cancer cell viability, migration, and invasion by suppressing PI3K/AKT/mTOR signaling and triggering autophagy.
ivermectin
The Marik Protocol: Ivermectin and Mebendazole for Cancer — Theory, Evidence, and Risks
A careful, evidence-based review of the Marik ivermectin + mebendazole cancer protocol — the proposed theory, what the human data actually shows, the dosing claims, and the real safety risks.
Fenbendazole + Photothermal Therapy Triggers Ferroptosis in Bladder Cancer (Advanced Science, 2026)
A June 2026 study in Advanced Science describes a nanoplatform combining fenbendazole with photothermal therapy to trigger ferroptosis and dual immunotherapy in orthotopic bladder cancer mouse models.
fenbendazole
Where to Buy Fenbendazole: Quality Verification, Purity Testing & Reliable Sources 2026
How to verify fenbendazole quality and purity before purchase. Reliable sources, third-party testing, counterfeit warnings, and what to look for in 2026.
Ketogenic Diet Enhances Mebendazole Therapy in Pediatric High-Grade Glioma (Cell Reports Medicine, 2026)
A June 2026 study in Cell Reports Medicine found that a ketogenic diet acts as a metabolic vehicle that enhances mebendazole's anti-tumor effects in juvenile mouse models of high-grade glioma, allowing lower drug doses and improved survival.
Journal Issues Expression of Concern on the 197-Patient Ivermectin + Mebendazole Study
Anticancer Research flagged the widely-shared Hulscher et al. study (84.4% clinical benefit) with a formal Expression of Concern: no control group, self-reported outcomes. The paper has not been retracted as of August 2026.
Nothing here yet.